To compare immunogenicity of HBV vaccine between 20 μg (0−1−6 month) and 60 μg (0−1 or 0−2 month) regimens in adults.
No differences in seroprotection rates among three vaccine groups at month 7/2/3 or 12.
The similar GMCs were observed in 20 μg (0−1−6 month) and 60 μg (0−2 month) groups at month 7/3.
A higher GMC level was induced by 3-dose (20 μg) HBV vaccine than by 2-dose (60 μg) at month 12.
All formulations of HBV vaccine were well tolerated with the incidence of adverse reactions <3%.